le (5f) were determined. The resulting enantiomers were resolved into enantiomers by analytical HPLC on modified amylose or cellulose chiral stationary phases. The viabilities of 4b, 4d, 5b, 5c in vitro, and in experiments in vivo antitumor effects of 1-N-ferrocenylethyl-4-nitroimidazole (4b) against murine solid tumor system Ca755 carcinoma were evaluated.
Ferrocenylalkyl硝基
咪唑(图4a-H ,5A-H中制备)经由所述的区域专一性反应α -烷基
二茂铁(羟基),FcCHR(OH)(1A-H ; FC =
二茂铁基; R = H,ME等, PR,我-Pr,PH,邻-Cl-PH,邻-I-PH),并在
水性有机介质中硝基
咪唑(H 2 O-CH 2
氯2)在HBF的存在下在室温4,内几分钟,收率很好。外消旋(R,S)-1- N-(苄基
二茂铁基)-
2-甲基-4-硝基咪唑的X射线结构数据(确定5f)。通过分析HPLC在改性的
直链淀粉或
纤维素手性固定相上将所得对映异构体拆分成对映异构体。评估了4b,4d,5b,5c 的体外活性以及在体内实验中1 - N-
二茂铁基乙基-4-硝基
咪唑(4b)对小鼠实体瘤系统Ca755癌的抗肿瘤作用。